Sutro Biopharma (STRO) Long-Term Debt Issuances (2020)

Sutro Biopharma's (STRO) quarterly Long-Term Debt Issuances came in at $25.0 million in Q1 2020.

Sutro Biopharma (STRO) Long-Term Debt Issuances (2020) Analysis & Trends

Sutro Biopharma has disclosed Long-Term Debt Issuances across 1 years of filings, most recently posting $25.0 million for Q1 2020.

  • Long-Term Debt Issuances for Q1 2020 came in at $25.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2020 was $25.0 million (changed N/A YoY), and the FY2020 annual result was $25.0 million, changed N/A from the prior year.
  • Long-Term Debt Issuances came in at $25.0 million for Q1 2020 at Sutro Biopharma.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $25.0 million in Q1 2020 to a low of $25.0 million in Q1 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 2.73 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Sutro Biopharma 252.04 Mn 252.04 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2020 25.00 Mn
Mar 31, 2020 25.00 Mn